Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peripheral Reduction of FGFR4 with Antisense Oligonucleotides Increases Metabolic Rate and Lowers Adiposity in Diet-Induced Obese Mice
Xing Yu, Lynnetta M. Watts, Vara Prasad Manchem, et al.
PLoS ONE (2013) Vol. 8, Iss. 7, pp. e66923-e66923
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Intestinal transport and metabolism of bile acids
Paul A. Dawson, Saul J. Karpen
Journal of Lipid Research (2014) Vol. 56, Iss. 6, pp. 1085-1099
Open Access | Times Cited: 477
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta
Nature Reviews Drug Discovery (2015) Vol. 15, Iss. 1, pp. 51-69
Closed Access | Times Cited: 381
Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins
Samir Softic, Jesse G. Meyer, Guo-Xiao Wang, et al.
Cell Metabolism (2019) Vol. 30, Iss. 4, pp. 735-753.e4
Open Access | Times Cited: 179
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Timothy P. Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 165
Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis
Takeshi Katafuchi, Makoto Makishima
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6046-6046
Open Access | Times Cited: 89
Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids
Courtney B. Ferrebee, Paul A. Dawson
Acta Pharmaceutica Sinica B (2015) Vol. 5, Iss. 2, pp. 129-134
Open Access | Times Cited: 102
Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy
Julian R.F. Walters
Nature Reviews Gastroenterology & Hepatology (2014) Vol. 11, Iss. 7, pp. 426-434
Closed Access | Times Cited: 101
Metabolic Messengers: fibroblast growth factor 15/19
Raffaella Maria Gadaleta, Antonio Moschetta
Nature Metabolism (2019) Vol. 1, Iss. 6, pp. 588-594
Closed Access | Times Cited: 94
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell, Alexander L. Breeze
Biochemical Society Transactions (2018) Vol. 46, Iss. 6, pp. 1753-1770
Open Access | Times Cited: 92
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4848-4858
Open Access | Times Cited: 58
Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism
Xiaoli Hu, Ylva Bonde, Gösta Eggertsen, et al.
Journal of Internal Medicine (2013) Vol. 275, Iss. 1, pp. 27-38
Closed Access | Times Cited: 99
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Gary D. Miller
American Journal of Lifestyle Medicine (2017) Vol. 13, Iss. 6, pp. 586-601
Open Access | Times Cited: 83
A big-data approach to understanding metabolic rate and response to obesity in laboratory mice
June K. Corrigan, Deepti Ramachandran, Yuchen He, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 67
FGFR4: A promising therapeutic target for breast cancer and other solid tumors
Kevin M. Levine, Kai Ding, Lyuqin Chen, et al.
Pharmacology & Therapeutics (2020) Vol. 214, pp. 107590-107590
Open Access | Times Cited: 66
Fibroblast Growth Factor Receptor 4 (FGFR4) Deficiency Improves Insulin Resistance and Glucose Metabolism under Diet-induced Obesity Conditions
Hongfei Ge, Jun Zhang, Yan Gong, et al.
Journal of Biological Chemistry (2014) Vol. 289, Iss. 44, pp. 30470-30480
Open Access | Times Cited: 47
Therapeutic uses of FGFs
Jun Zhang, Yang Li
Seminars in Cell and Developmental Biology (2015) Vol. 53, pp. 144-154
Closed Access | Times Cited: 42
Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference
Olga O. Golounina, Илдар Минниахметов, Р. Р. Салахов, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
The mood stabilizers lithium and valproate disrupt hepatic and intestinal farnesoid X receptor signalling and increase bile synthesis in the rat
Sofia Cussotto, Anna V. Golubeva, Alvaro Lopez Gallardo, et al.
Experimental Physiology (2025)
Open Access
Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis
F. Moreau, Bruna Brasil Brunao, Xiangyu Liu, et al.
Journal of Lipid Research (2022) Vol. 64, Iss. 2, pp. 100324-100324
Open Access | Times Cited: 16
Emerging drugs for the treatment of obesity
Christoffer Martinussen, Kirstine N. Bojsen‐Møller, Maria S. Svane, et al.
Expert Opinion on Emerging Drugs (2016) Vol. 22, Iss. 1, pp. 87-99
Closed Access | Times Cited: 26
Approaches Targeting the FGF–FGFR System: a Review of the Recent Patent Literature and Associated Advanced Therapeutic Agents
Corentin Herbert, Gilbert Lassalle, Chantal Alcouffe, et al.
Pharmaceutical Patent Analyst (2014) Vol. 3, Iss. 6, pp. 585-612
Closed Access | Times Cited: 23
Antisense oligonucleotide is a promising intervention for liver diseases
Kailing Lu, Qijing Fan, Xiaoju Zou
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 8
Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease
Michael F. Keating, Brian G. Drew, Anna C. Calkin
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 6
A big-data approach to understanding metabolic rate and response to obesity in laboratory mice
June K. Corrigan, Deepti Ramachandran, Yuchen He, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 6
New perspectives on the development of antiobesity drugs
Luca Costantino, Daniela Barlocco
Future Medicinal Chemistry (2015) Vol. 7, Iss. 3, pp. 315-336
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top